GET DAILY SIGNALSCreative Medical Technology Holdings (CELZ) Slides -25.8% Over 30 Days as Dilution Pressures Mount
Key Takeaways
- Creative Medical Technology Holdings (CELZ) fell approximately 25.8% over the last 30 days, sliding from a closing price of about $0.84 to roughly $0.62.
- The decline extends a broader multi-month downtrend following an extraordinary early-August volume and price spike.
- Dilution-related overhang—including an increase in authorized shares, a resale registration filing, and warrant exercises—has weighed on investor sentiment.
- The company continues to advance its regenerative medicine pipeline, including the Ultrasome osteoarthritis program (93% response rate in a pilot study) and the ADAPT trial for chronic lower back pain.
- Roth MKM analyst Jonathan Aschoff maintains a Buy rating on CELZ with a $20.00 price target.
- As a microcap with a market capitalization near $4.9 million and minimal revenue, CELZ carries elevated volatility and liquidity risk.
- For additional detail, explore Creative Medical Technology Holdings' Price Targets, Earnings, and Forecast pages.
- Traders and investors can also follow curated AI-driven strategies in the Trending AI Robots section.
A Closer Look at Creative Medical Technology Holdings (CELZ)
Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company headquartered in Phoenix, Arizona, focused on regenerative medicine and immunotherapy. The company develops both cell-based and cell-free therapeutic platforms across urology, neurology, endocrinology, orthopedics, and immunology. Its lead program, Olastrocel (CELZ-201), is being evaluated in the FDA-cleared ADAPT clinical trial for chronic lower back pain, while its Ultrasome platform targets knee osteoarthritis. The pipeline also includes diabetes programs such as CELZ-201 CREATE-1 and MyeloCelz, alongside the commercial products CaverStem and FemCelz. Through its majority-owned BioDefense subsidiary, the company is also advancing a data and discovery platform focused on toxic exposure. Investors follow CELZ closely for its clinical catalysts, intellectual property portfolio, and potential partnership opportunities, though its small scale and pre-revenue status make it a high-risk, high-volatility holding. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CELZ Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, CELZ declined from a closing price of approximately $0.84 to roughly $0.62, a drop of about 25.8%. The move was not driven by a single sharp session but by a steady, persistent drift lower punctuated by occasional rebounds. The broader three-month trend has been even more pronounced. After an extraordinary early-August spike that briefly carried shares above $1.40 on unusually heavy volume, the stock has retraced steadily. Measured from mid-August levels around $1.22, CELZ has fallen roughly 49% over the last quarter, underscoring a sustained downtrend rather than a short-lived correction. From what I see, reviewing the price action with Tickeron’s AI Trend Prediction Engine helped confirm the persistence of this pattern.
Factors Behind the Recent 30-Day Decline
Several factors contributed to the 30-day decline. First, the stock continued to unwind gains from its early-August volatility spike, with speculative interest fading as the move failed to hold. Second, capital-structure developments created a persistent dilution overhang. Stockholders had previously approved an increase in authorized common shares from 25 million to 100 million, and the company filed a resale registration statement covering millions of shares for holders. These actions, combined with earlier warrant-exercise agreements and newly issued inducement warrants, expanded the potential share supply and pressured the stock. Third, positive clinical updates—such as the late-October highlight of a 93% patient response rate in the Ultrasome knee osteoarthritis study—provided intermittent support but were not sufficient to offset the selling pressure. Finally, thin trading liquidity in this microcap amplified price swings in both directions.
Quarterly Drivers and Operational Progress
The quarterly performance reflects a sharp rise followed by a prolonged fade. In early August, CELZ experienced an exceptional single-day surge on extraordinary volume, briefly trading near $1.75 intraday before settling in the low-to-mid $1.20s. As that speculative momentum dissipated, the stock entered a multi-month downtrend. The dilution-related actions described above—the expanded share authorization, warrant exercises, and secondary offering registrations—continued to weigh on the shares throughout the period. At the same time, the company reported meaningful operational progress, including completion of enrollment across the ADAPT trial, new patent allowances, an expanded Ultrasome intellectual property filing, and increased ownership of its BioDefense subsidiary. These developments reinforced the fundamental story but did not reverse the downward price trajectory in a challenging environment for microcap biotechnology stocks.
Key Catalysts to Monitor Going Forward
Looking ahead, several factors are likely to shape CELZ's direction. Clinical catalysts remain central, including longer-term follow-up data from the ADAPT trial and the company's efforts to align with regulators on Phase 3 planning for Olastrocel in chronic lower back pain. Progress on the Ultrasome program—including the design of the next-stage, multi-center clinical study—and any partnership or licensing announcements could also influence sentiment. On the financial side, investors will monitor additional financing, share issuances, and warrant activity, given the dilution history. Regulatory developments, including potential RMAT evaluation for Olastrocel and FDA interactions, represent key milestones. Finally, broader biotechnology sector sentiment and risk appetite for microcap names will continue to affect trading dynamics. These factors are informational and do not constitute investment advice.
Exploring AI-Driven Trading Strategies
In my own analysis, I frequently turn to Tickeron’s AI tools to cross-check momentum signals and compare performance across similar names. One resource I find particularly useful is the Trending AI Robots page, which highlights top-performing automated strategies from a wide universe of bots. These can offer a data-driven lens on timing and risk management for volatile names like CELZ, helping align approaches with individual trading styles without replacing fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CELZ sees MACD Histogram crosses below signal line
CELZ saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 37 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELZ entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CELZ's RSI Oscillator exited the oversold zone, 31 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +12.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELZ advanced for three days, in 197 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.546) is normal, around the industry mean (3.498). P/E Ratio (-0.303) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. CELZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement